HighMark Wealth Management’s VanEck Biotech ETF BBH Stock Holding History

HighMark Wealth Management’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.3K	Hold	80	–	–	0.01%	267
2026 Q1	$15K	Hold	80	–	–	0.01%	251
2025 Q4	$15.1K	Hold	80	–	–	0.01%	271
2025 Q3	$13.3K	Hold	80	–	–	0.01%	267
2025 Q2	$12.3K	Hold	80	–	–	0.01%	281
2025 Q1	$12.6K	Hold	80	–	–	0.01%	247
2024 Q4	$12.6K	Hold	80	–	–	0.01%	257
2024 Q3	$14.2K	Hold	80	–	–	0.01%	245
2024 Q2	$13.5K	Hold	80	–	–	0.01%	237
2024 Q1	$13.3K	Hold	80	–	–	0.01%	237
2023 Q4	$13.2K	Hold	80	–	–	0.01%	234
2023 Q3	$12.5K	Hold	80	–	–	0.01%	236
2023 Q2	$12.5K	Hold	80	–	–	0.01%	233
2023 Q1	$13K	Hold	80	–	–	0.01%	260
2022 Q4	$12.8K	Hold	80	–	–	0.01%	221
2022 Q3	$11K	Hold	80	–	–	0.01%	228
2022 Q2	$12K	Hold	80	–	–	0.01%	218
2022 Q1	$13K	Buy	+80	New	+$13K	0.01%	223

Other funds holding BBH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

HighMark Wealth Management's BBH Position: Q2 2026 in Review

HighMark Wealth Management held its VanEck Biotech ETF (BBH) position steady in Q2 2026 at 80 shares worth $16.3K. The position accounts for 0.01% of the portfolio, ranked #267.

HighMark Wealth Management first reported a position in BBH in Q1 2022 and has held it in 18 quarters since. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

HighMark Wealth Management held 80 shares of VanEck Biotech ETF worth $16.3K as of Q2 2026.
HighMark Wealth Management left its VanEck Biotech ETF share count unchanged in Q2 2026.
VanEck Biotech ETF made up 0.01% of HighMark Wealth Management's portfolio in Q2 2026, its #267 holding.
HighMark Wealth Management first reported a position in VanEck Biotech ETF in Q1 2022 and has held it in 18 quarters since.
110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.